BGPT: Best Evidence: PARP-1 NAD depletion mitochondrial substrate limitation in neurotoxicity

Fuel Your Discoveries

Quick Explanation Copied

What the provided evidence most strongly supports

PARP-1 activation–linked NAD⁺ depletion is associated with brain injury phenotypes in a stroke model, and NAD⁺ replenishment (nicotinamide) can reduce infarct—with sex/genotype-dependent effects and important measurement caveats about mitochondrial vs cytosolic NAD⁺.
Mitochondrial substrate limitation can govern neurotoxicity-relevant outcomes (respiration/failure and lethality) in at least two provided mechanistic contexts: a substrate-supply-aware respirometry protocol (CRABS-ROC) and a Complex I substrate limitation mechanism in an organismal neurotoxicant sensitivity paradigm.

Confidence: moderate that the “PARP-1 → NAD⁺ depletion” part is relevant to acute neuroinjury (stroke), and moderate-to-low that the provided chain fully establishes “mitochondrial substrate limitation” as the dominant downstream mediator in neurotoxicity broadly.

Long Explanation

Battle-test: “PARP-1 NAD⁺ depletion → mitochondrial substrate limitation in neurotoxicity”

Scope rule (BGPT skeptical standard): I only connect concepts when the provided sources explicitly support that link. “Neurotoxicity” is broad; here the closest provided direct neuro injury evidence is cerebral ischemia (MCAO). I therefore separate: (1) PARP-1/NAD⁺ and (2) mitochondrial substrate limitation, then ask whether the provided evidence actually joins them causally.

Evidence map (what is known vs uncertain)

Known in provided data: PARP-1 genetic deletion and nicotinamide alter NAD⁺ dynamics and acute infarct size in MCAO, with strong sex-dependent patterns and documented limitations in distinguishing mitochondrial vs other NAD⁺ pools.
Known in provided data: A protocol-aware respirometry approach argues that conventional respiration readouts can miss substrate limitations and can reveal excess Complex I capacity alongside substrate supply constraints.
Known in provided data: In C. elegans with native gut microbiota, a specific bacterium (BIGb0170) increases rotenone lethality consistent with Complex I substrate limitation, and pyruvate partially rescues an ATP-loss phenotype; sensitivity is abolished in a Complex I mutant background.
Uncertain / not established from provided sources: The provided set does not directly demonstrate that PARP-1-driven NAD⁺ depletion causally produces mitochondrial substrate limitation in neurotoxic death. We have (a) NAD⁺/PARP-1 effects in stroke and (b) substrate limitation mechanisms in other settings—but the bridge mechanism is missing in the provided evidence.

Figure 1. MCAO: infarct size depends on sex/genotype and nicotinamide

Extracted from the provided stroke summary data (TTC infarct expressed as percent of contralateral corrected for edema, measured 24h post-ischemia).

Figure 2. Fold-change in infarct under nicotinamide (within genotype/sex)

Fold-change computed as (vehicle / nicotinamide) so values >1 represent protection (lower infarct with nicotinamide). Numeric values taken directly from the provided extracted infarct percentages.

Causal chain audit: where the “best evidence” is strong vs brittle

Link A: PARP-1 activity ↔ NAD⁺ depletion ↔ injury phenotype

Supported in MCAO context: PARP-1 KO and nicotinamide change NAD⁺ dynamics and infarct outcomes in ways that are consistent with NAD⁺-related bioenergetic failure shaping acute injury.
But mechanistic specificity is limited: The study explicitly notes that cytosolic vs mitochondrial NAD⁺ was not independently measured due to technical limitations, so the “mitochondrial NAD⁺ depletion” part of the chain remains unquantified directly.

Link B: NAD⁺ depletion ↔ mitochondrial substrate limitation

Not directly shown in provided material: The provided NAD⁺/PARP-1 stroke paper supports NAD⁺ changes and infarct outcome differences, but it does not report (in the provided extracted data) mitochondrial substrate pools/flux constraints that would demonstrate substrate limitation as the downstream mediator.
Substrate limitation is supported elsewhere: CRABS-ROC argues substrate supply can limit neuronal Complex I respiration in ways that conventional assays miss.
And a substrate-limitation model is consistent with neurotoxicant susceptibility: In C. elegans, rotenone lethality increased with BIGb0170 in a way attributed to Complex I substrate limitation and partially rescued by pyruvate; Complex I mutant background abolishes the effect—supporting the relevance of substrate limitation to neurotoxicity-like outcomes (chemical susceptibility).

Link C: “mitochondrial substrate limitation” should be measurable in neurotoxicity

Provided support is about measurability/assay design: CRABS-ROC explicitly motivates why substrate limitation can be missed.
Provided support is not yet about PARP→substrate-limitation causality: It remains unknown (from the provided evidence) whether PARP/NAD⁺ depletion drives substrate limitation specifically at Complex I under neurotoxic conditions.

Counterpoints / blind spots (high impact)

Sex/genotype effects are large: The stroke evidence shows that nicotinamide benefit differs strongly between groups, which implies that a single “one-size” PARP→NAD⁺ model may be incomplete without considering estrogen-related biology, NAD pool compartmentation, and downstream ATP/caspase mechanisms.
Measurement compartment problem: Without mitochondrial vs cytosolic NAD⁺ separation in the stroke study, it’s difficult to claim mitochondrial substrate-limitation causality via NAD⁺ pool depletion.
Substrate limitation evidence may not generalize across systems: CRABS-ROC is an assay/protocol advancement with a noted compromise and specialized substrate handling; the C. elegans microbiome result is organism- and substrate-context dependent.
“Neurotoxicity” might involve multiple death programs: The stroke study discusses caspase activity; substrate limitation may instead map onto ATP failure, ROS, or transport defects depending on context—not guaranteed to be a single mediator.

Best current verdict (based only on provided evidence)

Most supported sub-claim: In acute brain ischemia, NAD⁺ availability modulates injury, and PARP-1 genetic status affects NAD⁺ dynamics and infarct outcomes with strong sex-dependence.
Most supported independent sub-claim: Mitochondrial respiration can be substrate-limited in neural contexts, and substrate limitation can underlie chemical susceptibility mechanisms.
Weakest link in the exact “best evidence” chain: The provided set does not provide direct evidence that PARP-1/NAD⁺ depletion causes mitochondrial substrate limitation during neurotoxicity. Therefore the “unified” model is plausible but currently incompletely supported by direct causal measurements.

New testable split (what would disprove/repair the unified model)

Disproving experiment logic: Measure mitochondrial NAD⁺ compartment depletion and quantify Complex I substrate limitation simultaneously in the same neuroinjury paradigm, under PARP-1 inhibition/deletion and NAD⁺ replenishment. If NAD⁺ restoration rescues infarct without reducing substrate-limitation metrics, the “PARP→substrate limitation mediator” is weakened. (This proposal is driven by the stated compartment limitation and substrate-limitation measurement gaps in the provided sources.)

Feedback:

Updated: April 19, 2026

Top Data Sources Export MCP

1. The study investigates the cardioprotective effects of Salvianolic acid B (SalB) against angiotensin II-induced hypertrophy in neonatal rat cardiomyocytes, demonstrating that its protective mechanism involves the inhibition of PARP-1 and the restoration of NAD+ levels. [2014]

8QualityResults Limitations Context Blindspots Methods Sample

↗ Paper Review ↗ Full Paper

2. NAD+ metabolism links PARP-driven NAD+ depletion to β-cell necrosis and the CD38-cyclic ADP-ribose signaling pathway to glucose-induced insulin secretion, integrating pathways that govern β-cell death, regeneration, and function in diabetes. [2003]

8QualityResults Limitations Context Blindspots Methods Sample Conflict Data

↗ Paper Review ↗ Full Paper

3. The study reveals sex-specific NAD+ dynamics during cerebral ischemia in mice and shows that NAD+ repletion via nicotinamide or PARP-1 deletion provides sex- and genotype-dependent neuroprotection, with males and PARP-1 KO females benefiting most from NAD+ restoration while wild-type females show little to no benefit. [2013]

7QualityResults Limitations Context Blindspots Methods Sample Conflict Data

↗ Paper Review ↗ Full Paper

4. A positively charged hydrophilic vestibule within the human ER membrane complex (EMC) serves as a selectivity filter that uses charge repulsion to prevent translocation of positively charged C-terminal domains, thereby limiting mitochondrial tail-anchored protein misinsertion at the ER and reinforcing the positive-inside rule for TA and multipass membrane proteins. [2023]

9QualityResults Limitations Context Blindspots Methods Sample Conflict

↗ Paper Review ↗ Full Paper

5. We develop and calibrate the first mechanistically derived, thermodynamically consistent ping-pong kinetic model of the mitochondrial dicarboxylate carrier SLC25A10, parameterized by Bayesian inference to competition data, and demonstrate how substrate competition, mitochondrial morphology, and SDH deficiency reshape transporter fluxes, with experimental validation in Slc25a10-knockdown chromaffin cells. [2025]

9QualityResults Limitations Context Blindspots Methods Sample Conflict

↗ Paper Review ↗ Full Paper

Key Insight

The provided dataset supports two real halves—(i) PARP-1/NAD⁺ modulation of acute brain injury and (ii) substrate-limited mitochondrial respiration in neural contexts—but the unified “PARP → mitochondrial substrate limitation” link is currently a hypothesized bridge rather than a directly demonstrated causal pathway.

Keep Exploring

What direct mitochondrial substrate/flux measurements exist (in the provided dataset universe) for PARP-1 or NAD⁺-manipulated neuronal injury models?

How do NAD⁺ pool compartmentation differences (mitochondrial vs cytosolic) map onto sex-dependent neuroprotection in PARP/NAD⁺ frameworks?

Analysis Wizard

It will parse the provided extracted MCAO infarct percentages and compute within-group nicotinamide fold-protection stratified by sex/genotype, then output Plotly-ready arrays for figure reproducibility.

Hypothesis Graveyard

A single universal PARP-1→NAD⁺→infarct causal axis independent of sex is inconsistent with the strong sex-specific protection patterns reported in the stroke dataset; the model likely requires sex/genotype context.

“Substrate limitation is the only driver of neurotoxicity” is weakened by the provided stroke evidence emphasizing caspase-related outcomes and the lack (in the provided extraction) of direct substrate-limitation measurements in that same paradigm.

Potential Experiments

Measure mitochondrial vs cytosolic NAD⁺ compartments and Complex I substrate limitation metrics in the same MCAO cohorts stratified by sex and PARP-1 genotype, testing whether NAD⁺ restoration normalizes substrate limitation in parallel with infarct.

In a neurotoxicant susceptibility paradigm analogous to the C. elegans rotenone model, add PARP-1 perturbations and quantify whether the toxin sensitivity phenotype tracks substrate limitation markers and whether pyruvate rescue remains PARP-dependent or becomes PARP-independent.

Science Art

Science Movie

Make a narrated HD Science movie for this answer ($32 per minute)

Discussion

BGPT Bias

I may overweight measurement limitations explicitly stated in the sources, potentially underweighting mechanistic plausibility when direct causal assays are absent.

Get Ahead With Science Insights

Custom summaries of the latest cutting-edge research. Every Friday. No ads.

Search What Studies Actually Found

Search methods, samples, results, and limitations extracted from full-text papers.

Fuel Your Discoveries

Quick Explanation Copied

What the provided evidence most strongly supports

Long Explanation

Battle-test: “PARP-1 NAD+ depletion → mitochondrial substrate limitation in neurotoxicity”

Evidence map (what is known vs uncertain)

Figure 1. MCAO: infarct size depends on sex/genotype and nicotinamide

Figure 2. Fold-change in infarct under nicotinamide (within genotype/sex)

Causal chain audit: where the “best evidence” is strong vs brittle

Counterpoints / blind spots (high impact)

Best current verdict (based only on provided evidence)

New testable split (what would disprove/repair the unified model)

Top Data Sources ExportMCP

1. The study investigates the cardioprotective effects of Salvianolic acid B (SalB) against angiotensin II-induced hypertrophy in neonatal rat cardiomyocytes, demonstrating that its protective mechanism involves the inhibition of PARP-1 and the restoration of NAD+ levels. [2014]

2. NAD+ metabolism links PARP-driven NAD+ depletion to β-cell necrosis and the CD38-cyclic ADP-ribose signaling pathway to glucose-induced insulin secretion, integrating pathways that govern β-cell death, regeneration, and function in diabetes. [2003]

8. Native gut microbiota reshape C. elegans bioenergetics and mitochondrial toxin sensitivity, with BIGb0170 (Sphingobacterium multivorum) uniquely increasing rotenone lethality by restricting Complex I substrates, a deficit partially rescuable by pyruvate. [2026]

9. This study introduces the CRABS-ROC protocol, which reveals excess mitochondrial Complex I capacity in neurons and uncovers substrate limitations in mitochondrial respiration, particularly in the context of harlequin mutant mice with Complex I deficiency. [2025]

Ask a Follow-Up

Key Insight

Keep Exploring

What direct mitochondrial substrate/flux measurements exist (in the provided dataset universe) for PARP-1 or NAD+-manipulated neuronal injury models?

How do NAD+ pool compartmentation differences (mitochondrial vs cytosolic) map onto sex-dependent neuroprotection in PARP/NAD+ frameworks?

Analysis Wizard

It will parse the provided extracted MCAO infarct percentages and compute within-group nicotinamide fold-protection stratified by sex/genotype, then output Plotly-ready arrays for figure reproducibility.

Hypothesis Graveyard

A single universal PARP-1→NAD+→infarct causal axis independent of sex is inconsistent with the strong sex-specific protection patterns reported in the stroke dataset; the model likely requires sex/genotype context.

“Substrate limitation is the only driver of neurotoxicity” is weakened by the provided stroke evidence emphasizing caspase-related outcomes and the lack (in the provided extraction) of direct substrate-limitation measurements in that same paradigm.

Potential Experiments

Measure mitochondrial vs cytosolic NAD+ compartments and Complex I substrate limitation metrics in the same MCAO cohorts stratified by sex and PARP-1 genotype, testing whether NAD+ restoration normalizes substrate limitation in parallel with infarct.

In a neurotoxicant susceptibility paradigm analogous to the C. elegans rotenone model, add PARP-1 perturbations and quantify whether the toxin sensitivity phenotype tracks substrate limitation markers and whether pyruvate rescue remains PARP-dependent or becomes PARP-independent.

Science Art

Science Movie

Make a narrated HD Science movie for this answer ($32 per minute)

Discussion

BGPT Bias

I may overweight measurement limitations explicitly stated in the sources, potentially underweighting mechanistic plausibility when direct causal assays are absent.

Get Ahead With Science Insights

My BGPT

Trending

Battle-test: “PARP-1 NAD⁺ depletion → mitochondrial substrate limitation in neurotoxicity”

Top Data Sources Export MCP

What direct mitochondrial substrate/flux measurements exist (in the provided dataset universe) for PARP-1 or NAD⁺-manipulated neuronal injury models?

How do NAD⁺ pool compartmentation differences (mitochondrial vs cytosolic) map onto sex-dependent neuroprotection in PARP/NAD⁺ frameworks?

A single universal PARP-1→NAD⁺→infarct causal axis independent of sex is inconsistent with the strong sex-specific protection patterns reported in the stroke dataset; the model likely requires sex/genotype context.

Measure mitochondrial vs cytosolic NAD⁺ compartments and Complex I substrate limitation metrics in the same MCAO cohorts stratified by sex and PARP-1 genotype, testing whether NAD⁺ restoration normalizes substrate limitation in parallel with infarct.